Skip to main content
Premium Trial:

Request an Annual Quote

UK to Invest $7.7M in Genomics Research, with a Focus on Projects Using High-Throughput Sequencing

Premium

The UK's Technology Strategy Board said last week that it would invest up to £5 million ($7.7 million) in genomics-based research and development projects, particularly ones using high-throughput sequencing.

The board will begin taking proposals, which must be led by a business, on Oct. 12. After Nov. 18, a select group will be invited to submit full applications by Jan. 19, 2011, and a final decision will be made on Feb. 16.

The board said projects could cover a range of topics including the identification of economically important traits in livestock and crops, biomarker discovery, metagenomics, infectious disease, the development of vaccines and antimicrobials, and genetic improvements to commercially relevant organisms.

Additionally, all proposals must demonstrate commercial application as well as a "credible route to market."

Citing "amazing" technological progress in the field of genomics over the last decade, Ian Gray, chief executive of the strategy board, said in a statement that "the challenge for UK business is to capitalize on the opportunities provided by these technological advances."

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.